Trial Profile
A Two-part, Multicenter, Dose-titration Study Evaluating the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for the Treatment of Detrusor Overactivity Associated With a Neurological Condition in Pediatric Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Detrusor instability; Neurogenic bladder
- Focus Therapeutic Use
- Sponsors AbbVie; Allergan
- 15 Jan 2024 Status changed from active, no longer recruiting to completed.
- 23 Nov 2023 Planned primary completion date changed from 3 Nov 2023 to 5 Dec 2023.
- 23 Nov 2023 Status changed from recruiting to active, no longer recruiting.